including ArriVent BioPharma’s pan-EGFR mutant inhibitor furmonertinib – already approved in China and in phase 3 elsewhere for NSCLC with EGFR exon 20 insertions – and sunvozertinib from AZ ...
Moderna’s move into personalised cancer therapy continues to proceed at a rapid pace, with Merck & Co-partnered melanoma vaccine mRNA-4157 heading for a pivotal phase 3 programme after a phase ...
Dizal’s non-small cell lung cancer (NSCLC) candidate sunvozertinib will get a speedy FDA review after the agency granted priority review to the company’s new drug application. The company is ...
Aspirin reduced recurrence by 50% in PIK3CA-mutated colorectal cancer, the DCISionRT test earned FDA breakthrough status for predicting radiotherapy benefit in DCIS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback